NEW YORK (GenomeWeb News) — ProMetic Life Sciences has closed CA$6.6 million ($6.4 million) by selling 18.9 million subordinate shares for CA$.35 a share, the Montreal-based company said Tuesday.
ProMetic said it issued 13.3 million shares to Paradigm Capital for CA$4.7 million and 5.5 million shares to unidentified US institutional investors for CA$1.9 million.
Rodman & Renshaw Capital Group served as financial advisers for the financing, the company said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.